# Converd Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/converd-pharmaceutical

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.converd.com.cn
- Latest round: Series C (Aug 2, 2022)
- Investors on record: 5

## About

Based in Hangzhou, China and founded in 2012, Converd Pharmaceutical operates as an innovative drug developer specializing in oncolytic viral drugs. The company has applied for 75 domestic and foreign patents. The company has built a research and development center of over 1000 square meters and built a cytology laboratory, and an SPF certified laboratory animal house. In 2017, the company was awarded the certificate of Hangzhou enterprise high-tech research and development center. The chairman of the board, Fang Hu was the CEO of Shanghai Sunway Bio Co.,Ltd.

The company's business is a new drug creation industry involving medicinal chemistry, biology, pharmaceutical engineering, immunology, and pharmacological toxicology. The company has 3 major novel oncolytic virus drug development platforms, including adenovirus, caccinia virus and herpes simplex virus.

## Funding rounds

- Series C, Aug 2, 2022 — Lanshan Capital, Huafang Capital, Dongheng Industrial
- Series B, Dec 15, 2017 — Nanjing Venture Capital, CR Capital

## Investors

- Nanjing Venture Capital (https://capitalatlas.ai/funds/nanjing-venture-capital) — Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B
- Lanshan Capital (https://capitalatlas.ai/funds/lanshan-capital) — Series C
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series C
- Dongheng Industrial — Series C